AU1262501A - Compositions for transdermal and transmucosal administration of therapeutic agents - Google Patents

Compositions for transdermal and transmucosal administration of therapeutic agents

Info

Publication number
AU1262501A
AU1262501A AU12625/01A AU1262501A AU1262501A AU 1262501 A AU1262501 A AU 1262501A AU 12625/01 A AU12625/01 A AU 12625/01A AU 1262501 A AU1262501 A AU 1262501A AU 1262501 A AU1262501 A AU 1262501A
Authority
AU
Australia
Prior art keywords
transdermal
compositions
therapeutic agents
transmucosal administration
transmucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12625/01A
Other languages
English (en)
Inventor
Sam K. Attah-Poku
Marianna Foldvari
Martin King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaderm Laboratories Ltd
Original Assignee
Pharmaderm Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaderm Laboratories Ltd filed Critical Pharmaderm Laboratories Ltd
Publication of AU1262501A publication Critical patent/AU1262501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
AU12625/01A 1999-11-12 2000-11-10 Compositions for transdermal and transmucosal administration of therapeutic agents Abandoned AU1262501A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16510799P 1999-11-12 1999-11-12
US60165107 1999-11-12
US19540100P 2000-04-07 2000-04-07
US19554900P 2000-04-07 2000-04-07
US60195401 2000-04-07
US60195549 2000-04-07
PCT/CA2000/001323 WO2001035998A1 (en) 1999-11-12 2000-11-10 Compositions for transdermal and transmucosal administration of therapeutic agents

Publications (1)

Publication Number Publication Date
AU1262501A true AU1262501A (en) 2001-05-30

Family

ID=27389104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12625/01A Abandoned AU1262501A (en) 1999-11-12 2000-11-10 Compositions for transdermal and transmucosal administration of therapeutic agents

Country Status (3)

Country Link
EP (1) EP1265638A1 (de)
AU (1) AU1262501A (de)
WO (1) WO2001035998A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
FR2834215B1 (fr) * 2001-12-27 2004-07-16 Physica Composes amphiphiles a usage pharmaceutique ou cosmetique
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
ES2557475T3 (es) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
EP2685992A4 (de) 2011-03-15 2014-09-10 Phosphagenics Ltd Aminochinoline als kinasehemmer
JP6030630B2 (ja) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸
WO2014060447A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
JP2015536314A (ja) * 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
BR112016018625B1 (pt) * 2014-02-13 2020-10-13 Basf France S.A.S. capriloil alanina etil éster como um aprimorador de penetração
WO2015162195A1 (en) * 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
CN118512401A (zh) 2019-09-23 2024-08-20 迪迪艾斯研究公司 具有渗透促进剂的脂质囊泡组合物
KR20240037872A (ko) * 2021-03-24 2024-03-22 글로 파마, 인크. 미용제 전달을 위한 멀티솜 지질 소포

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093551B1 (de) * 1982-04-30 1991-01-16 Ajinomoto Co., Inc. Pharmazeutische Zusammensetzung
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
EP0364211B1 (de) * 1988-10-11 1994-12-21 Shire Holdings Ltd. Arzneimittelpräparat für perkutane Absorption
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
JP2640287B2 (ja) * 1990-07-16 1997-08-13 工業技術院長 リポソーム材料
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles

Also Published As

Publication number Publication date
WO2001035998A1 (en) 2001-05-25
EP1265638A1 (de) 2002-12-18

Similar Documents

Publication Publication Date Title
AU8206401A (en) Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
AU1585601A (en) Transdermal administration of huperzine
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
AU2513900A (en) Drug dosage unit for buccal administration of steroidal active agents
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
AU4332500A (en) Enhanced transdermal anesthesia of local anesthetic agents
EP1171117A4 (de) Langzeitverabreichung von pharmakologisch aktiven mitteln
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
EP1165048A4 (de) Zusammensetzungen und verfahren zur verbesserten verabreichung ionisierbarer hydrophober therapeutischer substanzen
AU7601998A (en) Composition and methods for transdermal delivery of acid labile drugs
EP1227821A4 (de) Therapeutische zusammensetzungen und verfahren zur verwendung davon
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
GB2355656B (en) Pharmaceutical compositions for oral and topical administration
AU1164601A (en) Therapeutic use and formulation
EP1154997A4 (de) Pharmazeutisch aktive verbindungen und ein verfahren zu ihrer herstellung
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU5460800A (en) Pharmaceutical transdermal compositions
AU1068101A (en) Transdermal administration of reboxetine
AU3869399A (en) Transdermal administration of fenoldopam
HUP0201405A3 (en) Pharmaceutical composition for therapeutic use of melatonin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase